Dr. Reddy’s Laboratories shares slide 6% on receiving non-compliance notice on Semaglutide filing
[hfe_template id='11223']
[ad_1]
Shares of Dr. Reddy’s Laboratories fell as much as 5.7% to an intraday low of Rs 1,181.60 on the BSE on Thursday, October 20, after the company disclosed that it had received a Notice of Non-Compliance (NON) from the Pharmaceutical Drugs Directorate of Canada. The notice pertains to the company’s Abbreviated New Drug Submission (ANDS) for its Semaglutide Injection. In an official statement, Dr. Reddy’s clarified that the NON outlines requests for additional information and clarifications on specific aspects of the submission. The company assured that it will submit a response promptly and within the stipulated time period. “We have received a Notice of Non-Compliance (NON) from the Pharmaceutical Drugs Directorate, Canada, regarding our Abbreviated New Drug Submission (ANDS) for Semaglutide Injection. The NON outlines requests for additional information and clarifications on specific aspects of the submission. We will submit a response at...